Differential Effects of Pravastatin, Simvastatin, and Atorvastatin on Ca2+ Release and Vascular Reactivity
- 1 July 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 34 (1) , 95-101
- https://doi.org/10.1097/00005344-199907000-00016
Abstract
The direct effects of the cholesterol-lowering agents, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors, on vascular smooth muscle responsiveness were examined by incubation of isolated aorta from normocholesterolemic rats with simvastatin, atorvastatin, or pravastatin. The smooth muscle contractions caused by phenylephrine were progressively inhibited with increasing concentrations of simvastatin. Similarly, atorvastatin at the higher concentration caused decreased responses to phenylephrine. In contrast, incubation with pravastatin had no significant effect at all concentrations studied. In Ca2+-free buffer, the transient contraction caused by phenylephrine, which results from intracellular release of Ca2+, also was inhibited by simvastatin and atorvastatin but not by pravastatin. In cultured rat aortic smooth muscle cells loaded with fura-2, increases in intracellular free-Ca2+ concentration ([Ca2+]i) induced by angiotensin II were markedly inhibited in cells incubated with simvastatin and atorvastatin but not pravastatin. The inhibitory effects of simvastatin and atorvastatin were reversed by mevalonate. These findings demonstrate that inhibition of HMG CoA reductase by using simvastatin and atorvastatin, but not pravastatin, has effects on vascular smooth muscle cell responsiveness that involve alteration of Ca2+ homeostasis through a mevalonate-dependent pathway.Keywords
This publication has 19 references indexed in Scilit:
- Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cellsBritish Journal of Pharmacology, 1997
- AtorvastatinDrugs, 1997
- Simvastatin Releases Ca2+ from a Thapsigargin-Sensitive Pool and Inhibits InsP3-Dependent Ca2+ Mobilization in Vascular Smooth Muscle CellsJournal of Cardiovascular Pharmacology, 1996
- Mevalonate availability affects human and rat resistance vessel function.Journal of Clinical Investigation, 1995
- Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesisEuropean Journal of Clinical Investigation, 1994
- Lovastin inhibits receptors-stimulated Ca2+-influx in retinoic acid differentiated U937 and HL-60 cellsCellular Signalling, 1994
- Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductaseAtherosclerosis, 1993
- Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733)Atherosclerosis, 1992
- Regulation of the mevalonate pathwayNature, 1990
- Receptor-Operated Calcium-Permeable Channels in Vascular Smooth MuscleJournal of Cardiovascular Pharmacology, 1989